Two drug combinations for advanced cancer with RAS mutations
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin clinical trials.
This trial tests two different treatment combinations (leflunomide alone or with MEK inhibitor and hydroxychloroquine) in people with advanced cancer that has a RAS mutation and has not responded to at least two prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 85 years old.
- You must have stage 4 (metastatic) cancer with a RAS mutation found in your tumor tissue within the last 5 years.
- You must have tried at least 2 prior standard cancer treatments that no longer work.
- Your cancer must be growing when you join.
- You need adequate blood counts, kidney function, and liver function (these will be checked by your doctor).
- If you could become pregnant, you must agree to use effective birth control during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GFH276 combined with either cetuximab or chemotherapy for people with certain cancers that have a specific genetic change called a RAS mutation. It focuses on solid tumors and pancreatic cancer (PDAC) and aims to see if the combination is safe and effective.
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
This trial tests if a combination of hydroxychloroquine, methotrexate, capecitabine, and bevacizumab works better than regorafenib for people with metastatic colorectal cancer that has a RAS gene mutation and has stopped responding to at least two prior treatments.
This trial tests whether a combination of targeted radiation (SBRT), chemotherapy (CAPEOX), a biologic drug (bevacizumab), and an immunotherapy (PD-1 inhibitor) can help people with a specific type of advanced colorectal cancer that cannot be removed by surgery. It is for patients whose tumors have a RAS gene mutation and are microsatellite stable (MSS).
This trial tests a new drug called XS-03 combined with standard chemotherapy and bevacizumab for people with metastatic colorectal cancer that has a specific genetic change called a RAS mutation. It aims to see if this combination is more effective than current treatments.
This trial tests a combination of targeted therapy drugs for people with advanced colorectal cancer who have already tried at least one other treatment. It aims to see if the drug combo can shrink tumors or slow the cancer's growth.
Hear when a new RAS Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.